Stocks · US
HALO
XNAS
Halozyme Therapeutics, Inc.
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-06 basis
P/E29.72x
P/B85.64x
P/S7.39x
EPS$3.64
ROE288.13%
ROA16.05%
Dividend yield0.00%
EV/EBITDA13.65x
Debt/Equity14.95
Free cash flow$806M
Returns and 52-week range
1W-1.65%
1M-0.43%
3M+36.52%
6M+72.52%
1Y+59.06%
YTD+56.05%
52W high$116.84
52W low$61.23
From 52W high-6.10%
Company
Peers in the same sector
| Company | Market cap | P/E | P/B | 1M |
|---|---|---|---|---|
| 페넘브라 | $12.5B | 77.78 | 8.16 | -1.59% |
| BrightSpring Health Services, Inc. Common Stock | $12.3B | 33.52 | 5.99 | +4.97% |
| Baxter International Inc. | $12.5B | — | 2.02 | -5.69% |
| Madrigal Pharmaceuticals, Inc. Common Stock | $11.4B | — | 21.78 | -8.25% |
| 10X 지노믹스 | $12.7B | — | 15.43 | +28.75% |
| DaVita Inc. | $11.4B | 13.45 | — | -1.95% |
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.